SYBX SYNLOGIC, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1527599 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-99.8%
TTM net income YoY59.2%
TTM EPS YoY79.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-511,875.0%
Net margin-291,987.5%
FCF margin-395,900.0%
EBITDA margin-507,537.5%
Returns
ROE-102.6%
ROA-49.0%
ROIC (approx.)-2,394.6%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets35.7%
Debt / equity0.00x
Current ratio2.80x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.36x
Accruals ratio17.4%
Payout ratio—
Capex / revenue175.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $8,000 | $3.37M | $1.18M | $1.75M |
| R&D expense | $43,000 | $9.15M | $43.97M | $52.04M | $47.13M |
| SG&A expense | $3.49M | $6.63M | $14.56M | $16.55M | $15.39M |
| Operating income | -$4.01M | -$40.95M | -$55.16M | -$67.42M | -$60.77M |
| Interest expense | — | $0 | $1,000 | $2,000 | $2,000 |
| Pretax income | -$1.00M | -$23.35M | -$61.26M | -$66.15M | — |
| Income tax | $0 | $5,000 | $14,000 | $0 | $0 |
| Net income | -$1.00M | -$23.36M | -$61.27M | -$66.15M | -$60.56M |
| EBITDA | -$4.01M | -$40.60M | -$53.20M | -$64.90M | -$58.32M |
| EPS (basic) | -0.08 | -1.92 | -9.42 | -13.83 | -1.09 |
| EPS (diluted) | -0.08 | -1.92 | -9.42 | -13.83 | -1.09 |
| Weighted avg. shares (diluted) | 12.31M | 12.20M | 6.50M | 4.78M | 55.33M |
| Balance sheet | |||||
| Cash & equivalents | $14.67M | $18.86M | $23.96M | $15.86M | $16.44M |
| Short-term investments | — | $0 | $23.79M | $61.77M | $112.15M |
| Current assets | $15.40M | $19.78M | $49.91M | $79.78M | $133.31M |
| PP&E, net | — | $0 | $5.60M | $7.32M | $9.09M |
| Total assets | $15.45M | $19.83M | $75.55M | $110.86M | $174.74M |
| Current liabilities | $3.58M | $7.08M | $30.29M | $12.12M | $10.08M |
| Total liabilities | $3.58M | $7.08M | $42.78M | $28.25M | $27.47M |
| Shareholders' equity | $11.86M | $12.75M | $32.77M | $82.61M | $147.27M |
| Shares outstanding | 11.70M | 11.70M | 9.19M | 4.45M | 69.70M |
| Cash flow statement | |||||
| Operating cash flow | -$4.36M | -$31.66M | -$51.61M | -$56.89M | -$52.20M |
| Capital expenditure | $0 | $14,000 | $214,000 | $728,000 | $679,000 |
| Free cash flow | -$4.36M | -$31.67M | -$51.83M | -$57.62M | -$52.88M |
| Investing cash flow | $167,000 | $25.34M | $38.77M | $58.35M | -$53.25M |
| Financing cash flow | $0 | $172,000 | $20.94M | -$2.04M | $89.38M |
| Depreciation & amortization | $0 | $347,000 | $1.96M | $2.52M | $2.44M |
| Stock-based compensation | $117,000 | $3.17M | $2.81M | $3.64M | $3.36M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.